{"ticker": {"uuid": "5002c68e-a29a-403d-a6d0-0040a88f124b", "symbol": "STOK", "name": "Stoke Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group", "summary": "The Goldman Sachs Group upgraded Stoke Therapeutics (NASDAQ:STOK) to a \"strong-buy\" rating. Despite the upgrade, the stock fell 6.1% to $29.46, remaining below the average analyst target price of $42.00. The company reported a narrower-than-expected quarterly loss but missed reve", "url": "https://www.marketbeat.com/instant-alerts/stoke-therapeutics-nasdaqstok-rating-increased-to-strong-buy-at-the-goldman-sachs-group-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T11:09:53", "published_display": "14 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target", "summary": "Goldman Sachs has initiated coverage on Stoke Therapeutics (STOK) with a \"Buy\" rating and set a price target of $44.00. This news follows Stoke Therapeutics' recent announcement of the appointment of Thomas McCauley as Chief Scientific Officer and the completion of enrollment in ", "url": "https://www.marketscreener.com/news/goldman-sachs-initiates-coverage-on-stoke-therapeutics-with-buy-rating-44-price-target-ce7f5edfd08aff26", "source_name": "marketscreener.com", "published_at": "2026-07-14T10:43:17", "published_display": "14 Jul 2026 10:43", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics appoints Thomas McCauley as CSO", "summary": "Stoke Therapeutics Inc. (NASDAQ:STOK) has appointed Thomas McCauley, Ph.D., as its new Chief Scientific Officer. McCauley brings over 25 years of experience and will lead the company's scientific strategy and pipeline expansion, particularly for its RNA medicines platform. The co", "url": "https://www.investing.com/news/company-news/stoke-therapeutics-appoints-thomas-mccauley-as-cso-93CH-4788241", "source_name": "Investing.com", "published_at": "2026-07-13T23:09:53", "published_display": "13 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer", "summary": "Stoke Therapeutics has appointed Thomas McCauley, Ph.D., as Chief Scientific Officer to lead its scientific strategy and research organization. McCauley brings over 25 years of experience in biotechnology, including leadership roles at Omega Therapeutics and Translate Bio. He wil", "url": "https://www.citybiz.co/article/873237/stoke-therapeutics-appoints-thomas-mccauley-as-chief-scientific-officer/", "source_name": "citybiz", "published_at": "2026-07-13T14:40:21", "published_display": "13 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOel9lc3Bha0NXQ3lpNGxBdWg4ZUlZN21ROXVMSm05anBsM1ZidWdsQ013SkhzblRmZk9UUWlvcWZqQnBuNEJ6XzI0SlJIRjVOUzRmclpWQWo3aUVUTlZVcHZjVXdjSWJXeWFkUHZLZWJNVGI2RVdtc1gySEdEejZsRUhrYlcxRHBMV1g5c3JwRUZxZVJ5V0JGSm03UzRtUjZzaEhPNnlWOW9EWktGaGc4dQ?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-13T13:27:53+00:00", "published_display": "13 Jul 2026 13:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer", "summary": "Stoke Therapeutics has appointed Dr. Thomas McCauley as its new Chief Scientific Officer. Dr. McCauley brings over 25 years of experience in leading R&D teams and translating scientific discoveries into clinical programs, with a focus on genetic medicines for rare diseases. In hi", "url": "https://www.contractpharma.com/breaking-news/stoke-therapeutics-taps-dr-thomas-mccauley-as-chief-scientific-officer/", "source_name": "Contract Pharma", "published_at": "2026-07-13T13:40:21", "published_display": "13 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RNA-medicine developer Stoke Therapeutics taps veteran scientist as new CSO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPY2JRRkJIXzlfNk1SdDhXOFNmZGxfVVoyUmU3b095ZW5KZG5oX05HTHRqNnBNUE43QWlUekFjN21oZTVFQndIYVR5M0ZOWWxnVklUUnBna0VDNE1aV3MxODVrQXNuMnpWNW9JVjFsSXpnT29OcGlNX3lHTDlSU1ZCaDhuT3pBUWQydjBxd0ZlOVlxLXVlMzZWTmdsc3VzTHEyR0NocnV6LUxMTDYxWjVuTlZlWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:30:00+00:00", "published_display": "13 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer", "summary": "Stoke Therapeutics has appointed Thomas McCauley, Ph.D., as its new Chief Scientific Officer. Dr. McCauley brings over 25 years of experience in R&D, focusing on translating scientific discoveries into new medicines, particularly in genetic rare diseases. He will lead Stoke's sci", "url": "https://www.businesswire.com/news/home/20260713413645/en/Stoke-Therapeutics-Appoints-Thomas-McCauley-Ph.D.-as-Chief-Scientific-Officer", "source_name": "Business Wire", "published_at": "2026-07-13T11:40:21", "published_display": "13 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential", "summary": "Goldman Sachs has initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and a $44 price target, citing the strong potential of its lead asset, zorevunersen, for Dravet syndrome. The investment bank believes zorevunersen could be the first disease-modifying ther", "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-initiates-stoke-therapeutics-stock-with-buy-rating-on-dravet-therapy-potential-93CH-4787762", "source_name": "Investing.com", "published_at": "2026-07-13T10:06:33", "published_display": "13 Jul 2026 10:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK", "summary": "Candriam S.C.A. increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 12.4% during the first quarter, now holding 502,020 shares valued at approximately $16.35 million. Despite a recent downgrade to \"Sell\" by Weiss Ratings, nine analysts maintain a \"Buy\" rating, with a conse", "url": "https://www.marketbeat.com/instant-alerts/filing-candriam-sca-has-1635-million-stake-in-stoke-therapeutics-inc-stok-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T15:10:20", "published_display": "12 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(STOK) and the Role of Price-Sensitive Allocations", "summary": "This article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), highlighting a mid-channel oscillation pattern and a strong risk-reward setup targeting a significant gain with minimal risk. It provides three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hed", "url": "https://news.stocktradersdaily.com/news_release/16/STOK_and_the_Role_of_Price-Sensitive_Allocations_071126062602_1783808762.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T18:26:00", "published_display": "11 Jul 2026 18:26", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?", "summary": "Stoke Therapeutics (STOK) is under scrutiny after completing enrollment for its Phase 3 EMPEROR study, despite recent removal from Russell indices. While the stock has seen significant long-term and short-term gains, its current $32.83 price is seen as undervalued against a fair ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/can-stoke-therapeutics-stok-justify-its-valuation-following", "source_name": "Simply Wall Street", "published_at": "2026-07-10T13:10:55", "published_display": "10 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgJBVV95cUxPNHFKTFJMdXV5TzRPR2Q3ZzYwSWVxTUlnbHM2NU81TkY5Q2JBbVFKeW1Eb2pHVDNuaW1LUkFoa1lWekZYTGppVENfeHdxa095N0NYTVVqRFU5bjJDeVhkZmlORmwzbHNIdTBEY1RpXzhrUmZ1T01YTEs1TVowWGYwZUpyUUdFS0FOSllxZ09lYWJ3OHVYcllFRFdEbG1JbHM3RGRIT1M1NkhnZWtLdUlJTTA4RHVqN0I1aVFZMWpBVHpENzNnNTNINUt0dVBkRWJ0NU9EeWQ0RzlVX1ZCV2hyUlZWLV8tcEduUVZ6S3NUZzR0T3Vkb0RTRVJHczU2SFN1X2tLbnBn?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-10T10:42:00+00:00", "published_display": "10 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of \"Moderate Buy\" from Analysts", "summary": "Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus \"Moderate Buy\" rating from analysts, with nine out of eleven research firms recommending the stock as a buy. The average 12-month price target is approximately $41.83, while the stock was trading at $32.83. The compa", "url": "https://www.marketbeat.com/instant-alerts/stoke-therapeutics-inc-nasdaqstok-receives-consensus-rating-of-moderate-buy-from-analysts-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T06:10:39", "published_display": "10 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows", "summary": "Stoke Therapeutics, a Nasdaq-listed genetic medicines company, is advancing its antisense oligonucleotide pipeline for rare diseases. The company focuses on developing RNA-based therapies designed to increase protein production to correct or compensate for underlying genetic defe", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/stoke-therapeutics-highlights-antisense-pipeline-as-genetic-medicine/69725712", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T17:10:14", "published_display": "08 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 79, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Stoke Therapeutics (STOK) Completing Phase 3 Enrollment For Zorevunersen In Dravet Syndrome", "summary": "Stoke Therapeutics (STOK) has completed Phase 3 enrollment for zorevunersen in Dravet syndrome, with plans for a rolling New Drug Application submission to the FDA in early 2027 and full data later that year. This milestone reinforces the importance of the program as a key near-t", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/how-investors-may-respond-to-stoke-therapeutics-stok-complet/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-07T23:09:35", "published_display": "07 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK", "summary": "Moran Wealth Management LLC has purchased a new position in Stoke Therapeutics (NASDAQ:STOK) during the first quarter, acquiring 40,552 shares valued at approximately $1.32 million. This move is part of several institutional adjustments in Stoke Therapeutics holdings, with other ", "url": "https://www.marketbeat.com/instant-alerts/filing-moran-wealth-management-llc-takes-132-million-position-in-stoke-therapeutics-inc-stok-2026-07-07/", "source_name": "MarketBeat", "published_at": "2026-07-07T14:42:11", "published_display": "07 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics holds the focus. Investors await the next evidence", "summary": "Stoke Therapeutics (STOK) remains a clinical-stage biotechnology company focused on RNA-targeting medicines for severe neurological diseases, with its stock performance closely tied to clinical data, regulatory milestones, and pipeline developments. Investors are primarily tracki", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/stoke-therapeutics-holds-the-focus-investors-await-the-next-evidence/69715285", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:42:11", "published_display": "07 Jul 2026 14:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades", "summary": "Stoke Therapeutics Chief Medical Officer Barry Ticho sold a total of 7,228 shares of company common stock on July 1, 2026, through two open-market transactions. These sales were conducted under a pre-established Rule 10b5-1 trading plan adopted in November 2025. The shares were s", "url": "https://www.stocktitan.net/sec-filings/STOK/form-4-stoke-therapeutics-inc-insider-trading-activity-5f38c2da8a83.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:40:19", "published_display": "06 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics faces earnings test after revenue miss By Investing.com", "summary": "Stoke Therapeutics (STOK) is preparing to announce its first-quarter results, facing scrutiny after a significant revenue miss last quarter. Analysts have recalibrated expectations, forecasting a loss of $0.81 per share on $7.07 million in revenue, an improvement from the prior q", "url": "https://ng.investing.com/news/earnings/stoke-therapeutics-faces-earnings-test-after-revenue-miss-93CH-2491195", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T09:10:39", "published_display": "06 Jul 2026 09:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT)", "summary": "This article provides key financial data and analyst estimates for Stoke Therapeutics, Inc. (0GT) on the Dusseldorf Stock Exchange. It covers stock forecasts, historical price performance, earnings reports, revenue, net income, EBITDA, and employee numbers, along with details on ", "url": "https://www.tradingview.com/symbols/DUS-0GT/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-07-06T02:10:37", "published_display": "06 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "STOK (NASDAQ) lists 7,228 RSUs and reports two 10b5-1 sales", "summary": "Stoke Therapeutics, Inc. (STOK) filed a Form 144 notice disclosing the proposed sale of 7,228 restricted stock units (RSUs) dated March 15, 2026. The filing also detailed two recent 10b5-1 sales executed by Baruch S. Ticho, involving 1,795 shares for $54,891.10 on June 1, 2026, a", "url": "https://www.stocktitan.net/sec-filings/STOK/144-stoke-therapeutics-inc-sec-filing-20a542c0b0fa.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:16", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome", "summary": "Stoke Therapeutics has completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome. The company plans to initiate a rolling New Drug Application (NDA) submission to the U.S. FDA in Q1 2027, with Phase 3 data e", "url": "https://www.businesswire.com/news/home/20260630626667/en/Stoke-Therapeutics-Announces-Completion-of-Enrollment-of-162-Patients-Into-the-Phase-3-EMPEROR-Study-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome", "source_name": "Business Wire", "published_at": "2026-07-01T07:09:30", "published_display": "01 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke completes Phase 3 enrollment for Dravet drug study", "summary": "Stoke Therapeutics has finished enrolling 162 patients in its Phase 3 EMPEROR study for zorevunersen, a potential treatment for Dravet syndrome. The company plans to initiate a rolling FDA New Drug Application submission in Q1 2027, with data from the study expected in Q3 2027. Z", "url": "https://grafa.com/en/news/united-states/stoke-therapeutics-emperor-phase3-enrollment-zorevunersen", "source_name": "grafa.com", "published_at": "2026-06-30T15:09:45", "published_display": "30 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Completes Enrollment in Phase 3 Study of Zorevunersen for Dravet Syndrome Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-completes-enrollment-phase-134720364.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:47:20+00:00", "published_display": "30 Jun 2026 13:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA", "summary": "Stoke Therapeutics has completed enrollment of 162 patients for its pivotal Phase 3 EMPEROR study of zorevunersen, a potential treatment for Dravet syndrome. The company anticipates a Phase 3 data readout in Q3 2027 and plans to initiate a rolling U.S. New Drug Application (NDA) ", "url": "https://www.stocktitan.net/sec-filings/STOK/8-k-stoke-therapeutics-inc-reports-material-event-06283eadf312.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:41:55", "published_display": "30 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027", "summary": "Stoke Therapeutics has completed enrollment of 162 patients for the primary analysis population in its Phase 3 EMPEROR study of zorevunersen, with approximately 50 patients reaching the 28-week primary endpoint. The company anticipates a Phase 3 data readout in Q3 2027 and plans ", "url": "https://www.tradingview.com/news/tradingview:b8733f6ca99e3:0-stoke-therapeutics-completes-enrollment-of-162-patients-in-phase-3-emperor-q3-2027-readout-rolling-nda-in-2027/", "source_name": "TradingView", "published_at": "2026-06-30T11:41:55", "published_display": "30 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke enrolls 162 patients in Phase 3 Dravet study", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPN0EyWXg3QjNoODI3OXRLc1hlQm5XVHJ6VXpvRnZYNGVfNi1WdndVNlp2ZUc5M1MxcUtxekk2NlpodnZGWXVjSWZxVVZIb0ZMUi1XSTFZRnlNOHdMT2VlZVJkOUZaWHIyWkx6dHFtSmtGckNCUkx1ZFI2dGZlazZmVGszNWJmeDJxaVBHaDRjc1FRc25aVG9VaWFzT0NweEJhcFVsQk80cTJ1ZDhYaFFPcEFVNTNOdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell Microcap Index", "summary": "Stoke Therapeutics, Inc. (NasdaqGS: STOK) has been removed from the Russell Microcap Index. The biotechnology company focuses on developing RNA-based medicines to treat severe diseases by upregulating protein expression, with its lead compound zorevunersen in clinical trials for ", "url": "https://www.marketscreener.com/news/stoke-therapeutics-inc-nasdaqgs-stok-dropped-from-russell-microcap-index-ce7f5fdeda8bff22", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:27:30", "published_display": "29 Jun 2026 04:27", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)?", "summary": "Stoke Therapeutics (STOK) was removed from several Russell indices, including the Russell Microcap and Russell 3000E, on June 27, 2026. This removal is expected to alter the company's investor base and trading patterns, potentially impacting its investment narrative and risk prof", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/does-broad-russell-index-removal-reshape-the-bull-case-for-s", "source_name": "Simply Wall Street", "published_at": "2026-06-29T03:10:30", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK", "summary": "Assenagon Asset Management S.A. reduced its stake in Stoke Therapeutics (NASDAQ:STOK) by 26.1% in the first quarter, selling 320,708 shares and retaining 907,015 shares valued at $29.5 million. Despite insider selling by General Counsel Jonathan Allan and insider Barry Ticho, ana", "url": "https://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-sells-320708-shares-of-stoke-therapeutics-inc-stok-2026-06-27/", "source_name": "MarketBeat", "published_at": "2026-06-27T08:10:31", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Stoke Therapeutics, Inc. \u2013 NASDAQ:STOK", "summary": "This article displays the \"Price to sales forward\" metric for Stoke Therapeutics, Inc. (NASDAQ: STOK) on the TradingView platform. It shows the current value, change, and percentage change for this financial indicator. The content is primarily a data display with minimal descript", "url": "https://www.tradingview.com/symbols/NASDAQ-STOK/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:31", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-announces-inducement-grants-200100875.html", "source_name": "Business Wire", "published_at": "2026-06-16T20:01:00+00:00", "published_display": "16 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNeU5YWXFUUzREa1ZwMkpZbGdsOG9TLVBuRmlUUDFhU1R5SlFueUZwZVpkVENYVWJELXVxRE53LTZGbmFXUTFsRTNDc0lsc3lHQ3lhMWlhTWFlUlBwbW1ybk9WLUxiV3VqX2pyOFpuNTJJcXc1OTAyXzNHSl9xNUNPU0x4QXJ6dXFqTkkzRDlWR21PcG9DaTA2VC1lWGVYRnZtcDluM1dUMEIwc2lGWmlCc3AyVlRGdw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxORDZ2VDhFQ2tUeTZwSFZmeGhwMmZCSGtMRTQzU0t5czMtSG5WbEM2a0ZITllGa2RKeE5CS1BEcU1xU1JXeEZtaDM2MlE2OTZ5TTlOdWJWU0Y3UTc3aUlqbWxBa3M5bXVMNHlHdkxreExPM1VSNHA3UWE4NG84MVhBM1VwdFRDZmNoNXZJX3Y4N0tIZnA2S2lxTHpIWG4yVUhwdUtiMmRiTQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "STOK - Stoke Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE45OEotdlk0eE9qRHBLQWNkWXN3bHdDZlpXcXA0eWtYVDZ3N1NwYm1IQTctRmxITFdFLVh1Q3dwUDBzWV8xYUE?oc=5", "source_name": "Finviz", "published_at": "2026-05-27T13:17:32+00:00", "published_display": "27 May 2026 13:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOd2pwMXB3eUxNTm1xeGQ0ak9VNWNtbTZUX3o5QmtxcXdNdVQ1ZkhGa0s5aXNlY09UUjJsZEZVYUxlSjNxV3YwVTl3RzhBcWJvNmtTSzZBMmdrYVZHZ2dpS2pEbmgwaUo1akl4V0RHaXVkN284bWU4eE9JMEtUYmUtazBtTTZXcDc1U0VTWjE5OFpmU0tMNmFYMm0yZ2pQcWFt?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stoke Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/23c080c8-42d0-328d-933a-8726edd19067/stoke-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-09T04:07:06+00:00", "published_display": "09 May 2026 04:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTHFrQ1dabUN5R3c2bVlJTl95ZnFjdXYwd1RDdk4zVlo1N1JJY2llWUhvLUJRcGZkMFlBdEU4SWNRLWZMeTUxZjBqTi03TGp3MHp1czlnR3hmdWRuMU1Bcngwc0FreFBrRk1hUE1IUHMwS2oyRTFJOGQzNnQtaXAzMmpCM08zT01WZEFDUWZjTFNULW1SeEt1d3U0MUJpNjgwM0MwaE0waUhUejBxVmVjSVZELWllUE43S0pIbk1nenVBUmxEbHJaWXJMTFgxcjFq?oc=5", "source_name": "BioSpace", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOTHZQRXFXSjhsc2hncjBPM0E0eW5RM2VtRnhHSXhhTDRqTy1VRHNMeHZXMV9lTEJtWW9IMEYxVHFrM05fM250NHl3SmZfMHE0SXFjdF9UNm5XWEZzMk9FU19YeEVkNkkya21JcHVkZG1HcDJlNW5fS2NEdzBHdWFIcWJVazItb1g4VUd5Z2kwdEZJSFZnWDg5aktSeG96LXNELWFUeUtiYw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stoke CEO Ian Smith to speak April 14 at Needham healthcare event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNNUc5WG1aVWdZY0dFblp0V0kxU2t3eTZ0dU5QUXkxTUV6bFFYenpKVDRCZkc1NHNLTHJHdFp0M2N0TVdESGZHUnVPR2xuekIxaGc3VlppaEtObzU5azFLN0tmb053UkZmUXlPdUtuSkFkWUxRX3N0Z2NUM1pLY2c0aHZaYnRMeEpPREk0Q1c4U0JkUnpkSHpPc0hpdmpVbUpkOTdiRGtZeUl4d2lzUlhtSjUzNmlleVZDanZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T20:03:31+00:00", "published_display": "08 Apr 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke adds drug-development veteran to board as Phase 3 moves ahead", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPcHFlU3FDclM2T3lwdFR3Tjk4SDhXSTRGUmtlNmtuX2RPWjBUalVfVFpMamZHNEJQOW5JazgzTlRsc1dncXNmY284NXZNSlBKTmhLYU1yYzV6b0RZS29aQVNXa2M4Y1ZhR09vUlVvNERja05qWnVRWlhCemtoZVJ4S2d6cF90ejQzb0otRmk0ZU8yN2FfRUhNVUVXY3hHakNFQ2NGM2U2bTJYMnVBeXZjNUxNWm8?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stoke Therapeutics (STOK) Quarterly Losses Test Newly Profitable Trailing Earnings Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxPbEFFZkp0QWIyYlRDc2lNV0lNLWhLNV9sNFRWc2JrYkdJWmRwRUdLRFJuNkJ4SlFHOGpKdHNzcGtpQUY5UDFiSVlNZnE2YmxNZk9wYW9CRmZWLVFLUE93a1pkc0dtUHNwYVh0SDgyVHRzemMwRS1EbnVFbEtlS3lmMm5CdE5XTl95VTI0bS1UeWUyS2VXelIxUGxEb0p1OU12TE5RblV4cmRheXdZUW9keTdxSnN6UWRrREIzRi1Wd0FTVzBrb25zeVcya0xkemMxMG53eDJlNmoxREw4MEdRLXh2bEtHN0RGZkZud0RKWDlMQ0tYQzFGM3R2eXg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Stoke Therapeutics (STOK) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQQVo0QnpXREVURy1seFF0emIzQ3NtNzlKSnRsNklaSUNxS2E2eVdqWHVWUHZYeENoU0IySU1HX2tvcmFXZmtBS3M2ellkSGdNSFZzTTlMSTl2MVgxUm0wOEtCWDNWRVBmQl90QjJOLXh2SGJ5T0RJNFNCZHVpWkZSVG5MQjFzV185X1k1LQ?oc=5", "source_name": "Market source", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE1ZSEZiTnN1dzBTZExCS1VucVBramh4X08tWDR2NGJEdFZSQTRxT1Z2dEtHVWRvY1BORUdBbGxScDVqRHRLZXN3NzB1ckdyZ0t1TUtZZUYyeWJaYWU5WVN4MkRVc2ZLR1dmd1U0N3k1Zw?oc=5", "source_name": "Investor's Business Daily", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMXl4TXpUN0Q1Tmh0enR2UTBpWjkyeXp3bVU2ZmRtX1hxalpOSnBGQmtmaVZNSnRoM01pak9CR3Z5VEhuVEF1UDJqQVJGVXdXOXh6U0ZZNU9xcDhyS1dYdDZ4RDg3d19WTjVIc1psZ0pCUmY2TW5CcDFHS0pTQWl4LXlWRi1DM1NoM2dTcVBFX0U1bngycDEzcjQySnZmck9PM3dYeU5UMy1DTlpkMy1zV28xRTBrWnR0cGczb1N3?oc=5", "source_name": "Biogen", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQNXlGUUlxclE4Unl6cE5kSFVubHBPanJiMmxzbHIweXFpZGM2YUowR3FoLVRrbnFrVXVKek9tNU8xTWFOYWxaSmN5WUQwLS1vd3c5ajBnNkNjVEs3MHg3WGpsSGtTTndxdVdWRG9FVGd0VWd2bHFWcGp0QnNkM2RpZWdYa1lXRGtwd3ZTclZMbFZvdGV0ZjhBYWphMjZ1Y2JJNEQ0eXRWM0xTRk5Kb0lWYTFxM21Mb3BZZ09zcmJqWmdzU2RybVVJ?oc=5", "source_name": "Biogen", "published_at": "2025-07-10T07:00:00+00:00", "published_display": "10 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNVUxBUmhVNXg4eEJUeXFYeW0yMjNDSWxRSktnMzRjTldpbHVWYm1Oa3pFZUthbmtzWi1mZDFaY1dzWXhFQ3RQZkc2TWNTLTMxd1hEZmQ5MlBNWHl2ZzhINHdIanE1c2RxZi0yTEdxd2NRUUJjSms3bDF2WXpTUllPN3p5T3MwOWZKcGpFdkZ3MEpCUTdyeHRQUG9lYk1wWFVmTnJBYWNNTTNOVUE5MXZnYVNNc21lVXFBM2dqeTB4SDdEeUU?oc=5", "source_name": "Biogen", "published_at": "2025-02-18T08:00:00+00:00", "published_display": "18 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group", "summary": "The Goldman Sachs Group upgraded Stoke Therapeutics (NASDAQ:STOK) to a \"strong-buy\" rating. Despite the upgrade, the stock fell 6.1% to $29.46, remaining below the average analyst target price of $42.00. The company reported a narrower-than-expected quarterly loss but missed reve", "url": "https://www.marketbeat.com/instant-alerts/stoke-therapeutics-nasdaqstok-rating-increased-to-strong-buy-at-the-goldman-sachs-group-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T11:09:53", "published_display": "14 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target", "summary": "Goldman Sachs has initiated coverage on Stoke Therapeutics (STOK) with a \"Buy\" rating and set a price target of $44.00. This news follows Stoke Therapeutics' recent announcement of the appointment of Thomas McCauley as Chief Scientific Officer and the completion of enrollment in ", "url": "https://www.marketscreener.com/news/goldman-sachs-initiates-coverage-on-stoke-therapeutics-with-buy-rating-44-price-target-ce7f5edfd08aff26", "source_name": "marketscreener.com", "published_at": "2026-07-14T10:43:17", "published_display": "14 Jul 2026 10:43", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics appoints Thomas McCauley as CSO", "summary": "Stoke Therapeutics Inc. (NASDAQ:STOK) has appointed Thomas McCauley, Ph.D., as its new Chief Scientific Officer. McCauley brings over 25 years of experience and will lead the company's scientific strategy and pipeline expansion, particularly for its RNA medicines platform. The co", "url": "https://www.investing.com/news/company-news/stoke-therapeutics-appoints-thomas-mccauley-as-cso-93CH-4788241", "source_name": "Investing.com", "published_at": "2026-07-13T23:09:53", "published_display": "13 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer", "summary": "Stoke Therapeutics has appointed Thomas McCauley, Ph.D., as Chief Scientific Officer to lead its scientific strategy and research organization. McCauley brings over 25 years of experience in biotechnology, including leadership roles at Omega Therapeutics and Translate Bio. He wil", "url": "https://www.citybiz.co/article/873237/stoke-therapeutics-appoints-thomas-mccauley-as-chief-scientific-officer/", "source_name": "citybiz", "published_at": "2026-07-13T14:40:21", "published_display": "13 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOel9lc3Bha0NXQ3lpNGxBdWg4ZUlZN21ROXVMSm05anBsM1ZidWdsQ013SkhzblRmZk9UUWlvcWZqQnBuNEJ6XzI0SlJIRjVOUzRmclpWQWo3aUVUTlZVcHZjVXdjSWJXeWFkUHZLZWJNVGI2RVdtc1gySEdEejZsRUhrYlcxRHBMV1g5c3JwRUZxZVJ5V0JGSm03UzRtUjZzaEhPNnlWOW9EWktGaGc4dQ?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-13T13:27:53+00:00", "published_display": "13 Jul 2026 13:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer", "summary": "Stoke Therapeutics has appointed Dr. Thomas McCauley as its new Chief Scientific Officer. Dr. McCauley brings over 25 years of experience in leading R&D teams and translating scientific discoveries into clinical programs, with a focus on genetic medicines for rare diseases. In hi", "url": "https://www.contractpharma.com/breaking-news/stoke-therapeutics-taps-dr-thomas-mccauley-as-chief-scientific-officer/", "source_name": "Contract Pharma", "published_at": "2026-07-13T13:40:21", "published_display": "13 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNA-medicine developer Stoke Therapeutics taps veteran scientist as new CSO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPY2JRRkJIXzlfNk1SdDhXOFNmZGxfVVoyUmU3b095ZW5KZG5oX05HTHRqNnBNUE43QWlUekFjN21oZTVFQndIYVR5M0ZOWWxnVklUUnBna0VDNE1aV3MxODVrQXNuMnpWNW9JVjFsSXpnT29OcGlNX3lHTDlSU1ZCaDhuT3pBUWQydjBxd0ZlOVlxLXVlMzZWTmdsc3VzTHEyR0NocnV6LUxMTDYxWjVuTlZlWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:30:00+00:00", "published_display": "13 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer", "summary": "Stoke Therapeutics has appointed Thomas McCauley, Ph.D., as its new Chief Scientific Officer. Dr. McCauley brings over 25 years of experience in R&D, focusing on translating scientific discoveries into new medicines, particularly in genetic rare diseases. He will lead Stoke's sci", "url": "https://www.businesswire.com/news/home/20260713413645/en/Stoke-Therapeutics-Appoints-Thomas-McCauley-Ph.D.-as-Chief-Scientific-Officer", "source_name": "Business Wire", "published_at": "2026-07-13T11:40:21", "published_display": "13 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential", "summary": "Goldman Sachs has initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and a $44 price target, citing the strong potential of its lead asset, zorevunersen, for Dravet syndrome. The investment bank believes zorevunersen could be the first disease-modifying ther", "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-initiates-stoke-therapeutics-stock-with-buy-rating-on-dravet-therapy-potential-93CH-4787762", "source_name": "Investing.com", "published_at": "2026-07-13T10:06:33", "published_display": "13 Jul 2026 10:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK", "summary": "Candriam S.C.A. increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 12.4% during the first quarter, now holding 502,020 shares valued at approximately $16.35 million. Despite a recent downgrade to \"Sell\" by Weiss Ratings, nine analysts maintain a \"Buy\" rating, with a conse", "url": "https://www.marketbeat.com/instant-alerts/filing-candriam-sca-has-1635-million-stake-in-stoke-therapeutics-inc-stok-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T15:10:20", "published_display": "12 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(STOK) and the Role of Price-Sensitive Allocations", "summary": "This article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), highlighting a mid-channel oscillation pattern and a strong risk-reward setup targeting a significant gain with minimal risk. It provides three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hed", "url": "https://news.stocktradersdaily.com/news_release/16/STOK_and_the_Role_of_Price-Sensitive_Allocations_071126062602_1783808762.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T18:26:00", "published_display": "11 Jul 2026 18:26", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?", "summary": "Stoke Therapeutics (STOK) is under scrutiny after completing enrollment for its Phase 3 EMPEROR study, despite recent removal from Russell indices. While the stock has seen significant long-term and short-term gains, its current $32.83 price is seen as undervalued against a fair ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/can-stoke-therapeutics-stok-justify-its-valuation-following", "source_name": "Simply Wall Street", "published_at": "2026-07-10T13:10:55", "published_display": "10 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgJBVV95cUxPNHFKTFJMdXV5TzRPR2Q3ZzYwSWVxTUlnbHM2NU81TkY5Q2JBbVFKeW1Eb2pHVDNuaW1LUkFoa1lWekZYTGppVENfeHdxa095N0NYTVVqRFU5bjJDeVhkZmlORmwzbHNIdTBEY1RpXzhrUmZ1T01YTEs1TVowWGYwZUpyUUdFS0FOSllxZ09lYWJ3OHVYcllFRFdEbG1JbHM3RGRIT1M1NkhnZWtLdUlJTTA4RHVqN0I1aVFZMWpBVHpENzNnNTNINUt0dVBkRWJ0NU9EeWQ0RzlVX1ZCV2hyUlZWLV8tcEduUVZ6S3NUZzR0T3Vkb0RTRVJHczU2SFN1X2tLbnBn?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-10T10:42:00+00:00", "published_display": "10 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of \"Moderate Buy\" from Analysts", "summary": "Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus \"Moderate Buy\" rating from analysts, with nine out of eleven research firms recommending the stock as a buy. The average 12-month price target is approximately $41.83, while the stock was trading at $32.83. The compa", "url": "https://www.marketbeat.com/instant-alerts/stoke-therapeutics-inc-nasdaqstok-receives-consensus-rating-of-moderate-buy-from-analysts-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T06:10:39", "published_display": "10 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows", "summary": "Stoke Therapeutics, a Nasdaq-listed genetic medicines company, is advancing its antisense oligonucleotide pipeline for rare diseases. The company focuses on developing RNA-based therapies designed to increase protein production to correct or compensate for underlying genetic defe", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/stoke-therapeutics-highlights-antisense-pipeline-as-genetic-medicine/69725712", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T17:10:14", "published_display": "08 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 79, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Stoke Therapeutics (STOK) Completing Phase 3 Enrollment For Zorevunersen In Dravet Syndrome", "summary": "Stoke Therapeutics (STOK) has completed Phase 3 enrollment for zorevunersen in Dravet syndrome, with plans for a rolling New Drug Application submission to the FDA in early 2027 and full data later that year. This milestone reinforces the importance of the program as a key near-t", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/how-investors-may-respond-to-stoke-therapeutics-stok-complet/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-07T23:09:35", "published_display": "07 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK", "summary": "Moran Wealth Management LLC has purchased a new position in Stoke Therapeutics (NASDAQ:STOK) during the first quarter, acquiring 40,552 shares valued at approximately $1.32 million. This move is part of several institutional adjustments in Stoke Therapeutics holdings, with other ", "url": "https://www.marketbeat.com/instant-alerts/filing-moran-wealth-management-llc-takes-132-million-position-in-stoke-therapeutics-inc-stok-2026-07-07/", "source_name": "MarketBeat", "published_at": "2026-07-07T14:42:11", "published_display": "07 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics holds the focus. Investors await the next evidence", "summary": "Stoke Therapeutics (STOK) remains a clinical-stage biotechnology company focused on RNA-targeting medicines for severe neurological diseases, with its stock performance closely tied to clinical data, regulatory milestones, and pipeline developments. Investors are primarily tracki", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/stoke-therapeutics-holds-the-focus-investors-await-the-next-evidence/69715285", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:42:11", "published_display": "07 Jul 2026 14:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades", "summary": "Stoke Therapeutics Chief Medical Officer Barry Ticho sold a total of 7,228 shares of company common stock on July 1, 2026, through two open-market transactions. These sales were conducted under a pre-established Rule 10b5-1 trading plan adopted in November 2025. The shares were s", "url": "https://www.stocktitan.net/sec-filings/STOK/form-4-stoke-therapeutics-inc-insider-trading-activity-5f38c2da8a83.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:40:19", "published_display": "06 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics faces earnings test after revenue miss By Investing.com", "summary": "Stoke Therapeutics (STOK) is preparing to announce its first-quarter results, facing scrutiny after a significant revenue miss last quarter. Analysts have recalibrated expectations, forecasting a loss of $0.81 per share on $7.07 million in revenue, an improvement from the prior q", "url": "https://ng.investing.com/news/earnings/stoke-therapeutics-faces-earnings-test-after-revenue-miss-93CH-2491195", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T09:10:39", "published_display": "06 Jul 2026 09:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT)", "summary": "This article provides key financial data and analyst estimates for Stoke Therapeutics, Inc. (0GT) on the Dusseldorf Stock Exchange. It covers stock forecasts, historical price performance, earnings reports, revenue, net income, EBITDA, and employee numbers, along with details on ", "url": "https://www.tradingview.com/symbols/DUS-0GT/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-07-06T02:10:37", "published_display": "06 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "STOK (NASDAQ) lists 7,228 RSUs and reports two 10b5-1 sales", "summary": "Stoke Therapeutics, Inc. (STOK) filed a Form 144 notice disclosing the proposed sale of 7,228 restricted stock units (RSUs) dated March 15, 2026. The filing also detailed two recent 10b5-1 sales executed by Baruch S. Ticho, involving 1,795 shares for $54,891.10 on June 1, 2026, a", "url": "https://www.stocktitan.net/sec-filings/STOK/144-stoke-therapeutics-inc-sec-filing-20a542c0b0fa.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:16", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome", "summary": "Stoke Therapeutics has completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome. The company plans to initiate a rolling New Drug Application (NDA) submission to the U.S. FDA in Q1 2027, with Phase 3 data e", "url": "https://www.businesswire.com/news/home/20260630626667/en/Stoke-Therapeutics-Announces-Completion-of-Enrollment-of-162-Patients-Into-the-Phase-3-EMPEROR-Study-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome", "source_name": "Business Wire", "published_at": "2026-07-01T07:09:30", "published_display": "01 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke completes Phase 3 enrollment for Dravet drug study", "summary": "Stoke Therapeutics has finished enrolling 162 patients in its Phase 3 EMPEROR study for zorevunersen, a potential treatment for Dravet syndrome. The company plans to initiate a rolling FDA New Drug Application submission in Q1 2027, with data from the study expected in Q3 2027. Z", "url": "https://grafa.com/en/news/united-states/stoke-therapeutics-emperor-phase3-enrollment-zorevunersen", "source_name": "grafa.com", "published_at": "2026-06-30T15:09:45", "published_display": "30 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Completes Enrollment in Phase 3 Study of Zorevunersen for Dravet Syndrome Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-completes-enrollment-phase-134720364.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:47:20+00:00", "published_display": "30 Jun 2026 13:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA", "summary": "Stoke Therapeutics has completed enrollment of 162 patients for its pivotal Phase 3 EMPEROR study of zorevunersen, a potential treatment for Dravet syndrome. The company anticipates a Phase 3 data readout in Q3 2027 and plans to initiate a rolling U.S. New Drug Application (NDA) ", "url": "https://www.stocktitan.net/sec-filings/STOK/8-k-stoke-therapeutics-inc-reports-material-event-06283eadf312.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:41:55", "published_display": "30 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027", "summary": "Stoke Therapeutics has completed enrollment of 162 patients for the primary analysis population in its Phase 3 EMPEROR study of zorevunersen, with approximately 50 patients reaching the 28-week primary endpoint. The company anticipates a Phase 3 data readout in Q3 2027 and plans ", "url": "https://www.tradingview.com/news/tradingview:b8733f6ca99e3:0-stoke-therapeutics-completes-enrollment-of-162-patients-in-phase-3-emperor-q3-2027-readout-rolling-nda-in-2027/", "source_name": "TradingView", "published_at": "2026-06-30T11:41:55", "published_display": "30 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke enrolls 162 patients in Phase 3 Dravet study", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPN0EyWXg3QjNoODI3OXRLc1hlQm5XVHJ6VXpvRnZYNGVfNi1WdndVNlp2ZUc5M1MxcUtxekk2NlpodnZGWXVjSWZxVVZIb0ZMUi1XSTFZRnlNOHdMT2VlZVJkOUZaWHIyWkx6dHFtSmtGckNCUkx1ZFI2dGZlazZmVGszNWJmeDJxaVBHaDRjc1FRc25aVG9VaWFzT0NweEJhcFVsQk80cTJ1ZDhYaFFPcEFVNTNOdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell Microcap Index", "summary": "Stoke Therapeutics, Inc. (NasdaqGS: STOK) has been removed from the Russell Microcap Index. The biotechnology company focuses on developing RNA-based medicines to treat severe diseases by upregulating protein expression, with its lead compound zorevunersen in clinical trials for ", "url": "https://www.marketscreener.com/news/stoke-therapeutics-inc-nasdaqgs-stok-dropped-from-russell-microcap-index-ce7f5fdeda8bff22", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:27:30", "published_display": "29 Jun 2026 04:27", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)?", "summary": "Stoke Therapeutics (STOK) was removed from several Russell indices, including the Russell Microcap and Russell 3000E, on June 27, 2026. This removal is expected to alter the company's investor base and trading patterns, potentially impacting its investment narrative and risk prof", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/does-broad-russell-index-removal-reshape-the-bull-case-for-s", "source_name": "Simply Wall Street", "published_at": "2026-06-29T03:10:30", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK", "summary": "Assenagon Asset Management S.A. reduced its stake in Stoke Therapeutics (NASDAQ:STOK) by 26.1% in the first quarter, selling 320,708 shares and retaining 907,015 shares valued at $29.5 million. Despite insider selling by General Counsel Jonathan Allan and insider Barry Ticho, ana", "url": "https://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-sells-320708-shares-of-stoke-therapeutics-inc-stok-2026-06-27/", "source_name": "MarketBeat", "published_at": "2026-06-27T08:10:31", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Stoke Therapeutics, Inc. \u2013 NASDAQ:STOK", "summary": "This article displays the \"Price to sales forward\" metric for Stoke Therapeutics, Inc. (NASDAQ: STOK) on the TradingView platform. It shows the current value, change, and percentage change for this financial indicator. The content is primarily a data display with minimal descript", "url": "https://www.tradingview.com/symbols/NASDAQ-STOK/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:31", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-announces-inducement-grants-200100875.html", "source_name": "Business Wire", "published_at": "2026-06-16T20:01:00+00:00", "published_display": "16 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNeU5YWXFUUzREa1ZwMkpZbGdsOG9TLVBuRmlUUDFhU1R5SlFueUZwZVpkVENYVWJELXVxRE53LTZGbmFXUTFsRTNDc0lsc3lHQ3lhMWlhTWFlUlBwbW1ybk9WLUxiV3VqX2pyOFpuNTJJcXc1OTAyXzNHSl9xNUNPU0x4QXJ6dXFqTkkzRDlWR21PcG9DaTA2VC1lWGVYRnZtcDluM1dUMEIwc2lGWmlCc3AyVlRGdw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxORDZ2VDhFQ2tUeTZwSFZmeGhwMmZCSGtMRTQzU0t5czMtSG5WbEM2a0ZITllGa2RKeE5CS1BEcU1xU1JXeEZtaDM2MlE2OTZ5TTlOdWJWU0Y3UTc3aUlqbWxBa3M5bXVMNHlHdkxreExPM1VSNHA3UWE4NG84MVhBM1VwdFRDZmNoNXZJX3Y4N0tIZnA2S2lxTHpIWG4yVUhwdUtiMmRiTQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "STOK - Stoke Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE45OEotdlk0eE9qRHBLQWNkWXN3bHdDZlpXcXA0eWtYVDZ3N1NwYm1IQTctRmxITFdFLVh1Q3dwUDBzWV8xYUE?oc=5", "source_name": "Finviz", "published_at": "2026-05-27T13:17:32+00:00", "published_display": "27 May 2026 13:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOd2pwMXB3eUxNTm1xeGQ0ak9VNWNtbTZUX3o5QmtxcXdNdVQ1ZkhGa0s5aXNlY09UUjJsZEZVYUxlSjNxV3YwVTl3RzhBcWJvNmtTSzZBMmdrYVZHZ2dpS2pEbmgwaUo1akl4V0RHaXVkN284bWU4eE9JMEtUYmUtazBtTTZXcDc1U0VTWjE5OFpmU0tMNmFYMm0yZ2pQcWFt?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/23c080c8-42d0-328d-933a-8726edd19067/stoke-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-09T04:07:06+00:00", "published_display": "09 May 2026 04:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTHFrQ1dabUN5R3c2bVlJTl95ZnFjdXYwd1RDdk4zVlo1N1JJY2llWUhvLUJRcGZkMFlBdEU4SWNRLWZMeTUxZjBqTi03TGp3MHp1czlnR3hmdWRuMU1Bcngwc0FreFBrRk1hUE1IUHMwS2oyRTFJOGQzNnQtaXAzMmpCM08zT01WZEFDUWZjTFNULW1SeEt1d3U0MUJpNjgwM0MwaE0waUhUejBxVmVjSVZELWllUE43S0pIbk1nenVBUmxEbHJaWXJMTFgxcjFq?oc=5", "source_name": "BioSpace", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOTHZQRXFXSjhsc2hncjBPM0E0eW5RM2VtRnhHSXhhTDRqTy1VRHNMeHZXMV9lTEJtWW9IMEYxVHFrM05fM250NHl3SmZfMHE0SXFjdF9UNm5XWEZzMk9FU19YeEVkNkkya21JcHVkZG1HcDJlNW5fS2NEdzBHdWFIcWJVazItb1g4VUd5Z2kwdEZJSFZnWDg5aktSeG96LXNELWFUeUtiYw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke CEO Ian Smith to speak April 14 at Needham healthcare event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNNUc5WG1aVWdZY0dFblp0V0kxU2t3eTZ0dU5QUXkxTUV6bFFYenpKVDRCZkc1NHNLTHJHdFp0M2N0TVdESGZHUnVPR2xuekIxaGc3VlppaEtObzU5azFLN0tmb053UkZmUXlPdUtuSkFkWUxRX3N0Z2NUM1pLY2c0aHZaYnRMeEpPREk0Q1c4U0JkUnpkSHpPc0hpdmpVbUpkOTdiRGtZeUl4d2lzUlhtSjUzNmlleVZDanZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T20:03:31+00:00", "published_display": "08 Apr 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke adds drug-development veteran to board as Phase 3 moves ahead", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPcHFlU3FDclM2T3lwdFR3Tjk4SDhXSTRGUmtlNmtuX2RPWjBUalVfVFpMamZHNEJQOW5JazgzTlRsc1dncXNmY284NXZNSlBKTmhLYU1yYzV6b0RZS29aQVNXa2M4Y1ZhR09vUlVvNERja05qWnVRWlhCemtoZVJ4S2d6cF90ejQzb0otRmk0ZU8yN2FfRUhNVUVXY3hHakNFQ2NGM2U2bTJYMnVBeXZjNUxNWm8?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics (STOK) Quarterly Losses Test Newly Profitable Trailing Earnings Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxPbEFFZkp0QWIyYlRDc2lNV0lNLWhLNV9sNFRWc2JrYkdJWmRwRUdLRFJuNkJ4SlFHOGpKdHNzcGtpQUY5UDFiSVlNZnE2YmxNZk9wYW9CRmZWLVFLUE93a1pkc0dtUHNwYVh0SDgyVHRzemMwRS1EbnVFbEtlS3lmMm5CdE5XTl95VTI0bS1UeWUyS2VXelIxUGxEb0p1OU12TE5RblV4cmRheXdZUW9keTdxSnN6UWRrREIzRi1Wd0FTVzBrb25zeVcya0xkemMxMG53eDJlNmoxREw4MEdRLXh2bEtHN0RGZkZud0RKWDlMQ0tYQzFGM3R2eXg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Stoke Therapeutics (STOK) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQQVo0QnpXREVURy1seFF0emIzQ3NtNzlKSnRsNklaSUNxS2E2eVdqWHVWUHZYeENoU0IySU1HX2tvcmFXZmtBS3M2ellkSGdNSFZzTTlMSTl2MVgxUm0wOEtCWDNWRVBmQl90QjJOLXh2SGJ5T0RJNFNCZHVpWkZSVG5MQjFzV185X1k1LQ?oc=5", "source_name": "Market source", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE1ZSEZiTnN1dzBTZExCS1VucVBramh4X08tWDR2NGJEdFZSQTRxT1Z2dEtHVWRvY1BORUdBbGxScDVqRHRLZXN3NzB1ckdyZ0t1TUtZZUYyeWJaYWU5WVN4MkRVc2ZLR1dmd1U0N3k1Zw?oc=5", "source_name": "Investor's Business Daily", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMXl4TXpUN0Q1Tmh0enR2UTBpWjkyeXp3bVU2ZmRtX1hxalpOSnBGQmtmaVZNSnRoM01pak9CR3Z5VEhuVEF1UDJqQVJGVXdXOXh6U0ZZNU9xcDhyS1dYdDZ4RDg3d19WTjVIc1psZ0pCUmY2TW5CcDFHS0pTQWl4LXlWRi1DM1NoM2dTcVBFX0U1bngycDEzcjQySnZmck9PM3dYeU5UMy1DTlpkMy1zV28xRTBrWnR0cGczb1N3?oc=5", "source_name": "Biogen", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQNXlGUUlxclE4Unl6cE5kSFVubHBPanJiMmxzbHIweXFpZGM2YUowR3FoLVRrbnFrVXVKek9tNU8xTWFOYWxaSmN5WUQwLS1vd3c5ajBnNkNjVEs3MHg3WGpsSGtTTndxdVdWRG9FVGd0VWd2bHFWcGp0QnNkM2RpZWdYa1lXRGtwd3ZTclZMbFZvdGV0ZjhBYWphMjZ1Y2JJNEQ0eXRWM0xTRk5Kb0lWYTFxM21Mb3BZZ09zcmJqWmdzU2RybVVJ?oc=5", "source_name": "Biogen", "published_at": "2025-07-10T07:00:00+00:00", "published_display": "10 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNVUxBUmhVNXg4eEJUeXFYeW0yMjNDSWxRSktnMzRjTldpbHVWYm1Oa3pFZUthbmtzWi1mZDFaY1dzWXhFQ3RQZkc2TWNTLTMxd1hEZmQ5MlBNWHl2ZzhINHdIanE1c2RxZi0yTEdxd2NRUUJjSms3bDF2WXpTUllPN3p5T3MwOWZKcGpFdkZ3MEpCUTdyeHRQUG9lYk1wWFVmTnJBYWNNTTNOVUE5MXZnYVNNc21lVXFBM2dqeTB4SDdEeUU?oc=5", "source_name": "Biogen", "published_at": "2025-02-18T08:00:00+00:00", "published_display": "18 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 57, "sentiment_summary": {"positive": 20, "negative": 6, "neutral": 31, "score": 57, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.9, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}], "positive_events": 20, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 31.38, "latest_week": "2026-07-10", "one_week_move": -4.0, "four_week_move": 5.2, "twelve_week_move": -15.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.535008, "market_dynamics_buy_signal": false, "relative_strength": -5.769768, "fair_value_gap": 97.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.1061, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.0% over one week, +5.2% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 7}, {"label": "MarketBeat", "count": 6}, {"label": "TradingView", "count": 4}, {"label": "Business Wire", "count": 3}, {"label": "Simply Wall Street", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Biogen", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.0% over one week, +5.2% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group"}], "updated_at": "2026-07-16T00:45:53.759368+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}